期刊文献+

ITGβ1、IFI16、TTR血清水平与妊娠期高血压疾病进展程度关联性及临床表达意义探究 被引量:7

Correlation of serum levels of ITGβ1,IFI16 and TTR with the degree of progression of hypertension in pregnancy and their clinical expression significance
原文传递
导出
摘要 目的探究整合素β1(integrinβ1,ITGβ1)、人γ干扰素诱导蛋白16(interferon-inducible protein 16,IFI16)、转甲状腺素蛋白(transthyretin,TTR)血清水平与妊娠期高血压疾病进展程度关联性及临床表达意义。方法选取2018年11月-2020年1月在攀枝花市中心医院住院分娩的妊娠期高血压疾病患者91例为研究组,另随机选取同期正常妊娠孕妇91例为对照组。对比两组血清ITGβ1、IFI16、TTR水平,采用Spearson秩相关分析血清各指标与妊娠期高血压疾病进展程度的相关性,采用受试者工作(receiver operating characteristic,ROC)曲线分析探讨血清各指标对妊娠期高血压疾病患者妊娠结局的预测价值。结果研究组血清ITGβ1、IFI16水平高于对照组,血清TTR水平低于对照组(P<0.05);妊娠期高血压疾病进展程度与血清ITGβ1、IFI16水平呈正相关,与血清TTR水平呈负相关(P<0.05);血清ITGβ1>2.38 ng/ml、IFI16>24.39 ng/ml、TTR≤315.08 mg/L联合预测妊娠期高血压疾病患者有无不良妊娠结局的曲线下面积(area under the carve,AUC)为0.861,大于各指标单一预测的AUC(0.782、0.813、0.790),联合预测的敏感度、特异度分别为80.00%、81.82%。结论妊娠期高血压疾病患者血清ITGβ1、IFI16表达明显升高,血清TTR表达水平降低,与妊娠期高血压疾病的发生及病情进展程度密切相关,且能辅助临床预测患者妊娠结局。 Objective To investigate the association of serum levels of integrinβ1(ITGβ1),interferon-inducible protein 16(IFI16)and transthyretin(TTR)with the disease progression of hypertension during pregnancy and their clinical expression significance.Methods From November 2018 to January 2020,91 patients with hypertension during pregnancy who delivered babies at the Central Hospital of Panzhihua City were selected as the study group,and 91 normal pregnant women during the same period were randomly selected as the control group.The serum levels of ITGβ1,IFI16 and TTR of the two groups were compared.Spearson rank correlation analysis was conducted to explore the correlation between the above-mentioned serum indexes and the disease progression of hypertension during pregnancy.The receiver operating characteristic curve was used to analyze the predictive value of serum indexes for pregnancy outcomes of the patients with hypertensive disorder of pregnancy.Results Serum levels of ITGβ1 and IFI16 were higher in the study group than in the control group,while serum level of TTR was lower in the study group than in the control group(P<0.05).The degree of progression of hypertension during pregnancy was positively correlated with serum levels of ITGβ1 and IFI16,but negatively correlated with serum level of TTR(P<0.05).The area under the curve(AUC)of serum ITGβ1>2.38 ng/ml,IFI16>24.39 ng/ml and TTR≤315.08 mg/L combined to predict the presence or absence of adverse pregnancy outcomes in the hypertensive patients during pregnancy was 0.861,which was greater than the single predicted AUC of each index(0.782,0.813,0.790),and the sensitivity and specificity of the combined prediction were 80.00%and 81.82%,respectively.Conclusion The expression of serum ITGβ1 and IFI16 in the patients with pregnancy-induced hypertension increased significantly,but the expression of serum TTR decreased,which were closely related to the occurrence and progression of pregnancy-induced hypertension,and could assist clinical prediction of pregnancy outcomes of the patients.
作者 李驰花 曾仲萍 刘秀丽 谢佳 刘芳 马玥 唐媛 刘琴 LI Chi-hua;ZENG Zhong-ping;LIU Xiu-li;XIE Jia;LIU Fang;MA Yue;TANG Yuan;LIU Qin(The Central Hospital of Panzhihua City,Panzhihua,Sichuan 617067,China;Panzhihua Municipal Maternal and Child Health Care Hospital,Panzhihua,Sichuan 617000,China)
出处 《实用预防医学》 CAS 2021年第6期691-694,共4页 Practical Preventive Medicine
关键词 妊娠期高血压疾病 整合素Β1 人γ干扰素诱导蛋白16 转甲状腺素蛋白 病情进展程度 妊娠结局 hypertension during pregnancy integrinβ1 interferon-inducible protein 16 transthyretin protein degree of disease progression pregnancy outcome
  • 相关文献

参考文献15

二级参考文献132

  • 1蔡霞,曲广第,耿丽红,马金英,张巍,马旭东.妊娠高血压综合征患者胎盘整合素α1、β1的表达与细胞凋亡[J].中华围产医学杂志,2005,8(1):13-16. 被引量:4
  • 2American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy.Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy [J]. Obstet Gynecol, 2013, 122(5):1122-1131.
  • 3Magee LA, Pels A, Helewa M, et al.Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary[J]. J Obstet Gynaecol Can, 2014, 36(5):416-441.
  • 4Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance[J]. BMJ, 2010, 341 :c2207.
  • 5Lowe SA, Bowyer L, Lust K, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014[J]. Aust N Z J Obstet Gynaecol, 2015, 55(1):11-16.
  • 6Campos-Outcah D Sr. US Preventive Services Task Force: the gold standard of evidence-based prevention[J]. J Fam Pract, 2005, 54(6):517-519.
  • 7Magee LA, Hdewa M, Momquin JM, et al. Diagnosis, evaluation,and management of the hypertensive disorders of pregnancy[J]. J Obstet Gynaeeol Can, 2008, 30 (Suppl): S1-48.
  • 8Cote AM, Brown MA, Laln E, et al. Diagnostic accuracy of urinary spot protein: creatiniue ratio for proteinuria in hypertensive pregnant women: systematic review[J]. BMJ, 2008, 336(7651): 1003-1006.
  • 9Churchill D, Beevers GD, Meher S, et al, Diuretics for preventing pre-eclampsia[J]. Cochrane Database Syst Rev, 2007, 24 (1):CD004451.
  • 10McCoy S, Baldwin K. Pharmacotherapeutie options for the treatment of preeelampsia[J]. Am J Health Syst Pharm, 2009, 66(4):337-344.

共引文献1342

同被引文献67

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部